- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Policy on anti-corruption, gifts and hospitality
- Contact us
- Thank you
Lung Bioengineering has acquired the XPS™ for use in its new Jacksonville EVLP center
Lung Bioengineering purchased an XVIVO Perfusion System (XPS™) with STEEN Solution Perfusate from XVIVO Perfusion AB (STO: XVIVO) for use in its Jacksonville Ex Vivo Lung Perfusion (EVLP) center. XVIVO Perfusion will continue to provide training and supplies for use of their machines by transplant hospitals to re-evaluate donated lungs that have initially been deemed unsuitable for transplant. Lung Bioengineering and XVIVO Perfusion will also continue to cooperate and collaborate in promoting the use of centralized XPS EVLP services that could increase the supply of transplantable lungs to address needless patient deaths on the transplant waitlist.
On April 26, 2019 XVIVO received Premarket approval (PMA) from the FDA for XPS with STEEN Solution Perfusate for sale on the American market. The XPS with STEEN Solution Perfusate was the first medical device that was approved for EVLP of initially unacceptable donated lungs.
“We are very pleased that the collaboration agreement is extended to Lung Bioengineering´s new Jacksonville facility. United Therapeutics’ impressive history of developing and delivering innovative and effective therapies for severe lung diseases makes them the ideal partner for XVIVO Perfusion in our quest to prevent mortality due to organ shortages,” said Dr. Magnus Nilsson, Chief Executive Officer of XVIVO Perfusion.
August 23, 2019
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159, email@example.com
Magnus Nilsson, CEO, +46 31 788 2150, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication, through the agency of the contact person set out above, at 08:00 am CET on August 23, 2019.